JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

Home・Elenco Azioni・Lantheus Holdings Inc

Search

Lantheus Holdings Inc

Chiusa

SettoreSettore sanitario

87.74 3.02

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

84.46

Massimo

88.16

Metriche Chiave
By Trading Economics
Entrata	26M 54M
Vendite	23M 407M
P/E Media del settore	24.666 67.147
Margine di Profitto	13.296
Dipendenti	1,193
EBITDA	31M 98M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+8.23% upside

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	484M 5.5B
Apertura precedente	84.72
Chiusura precedente	87.74

Notizie sul Sentiment di mercato

By Acuity

6%

94%

2 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

79.24 / 103.64 Supporto e resistenza

Lantheus Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 mag 2026, 22:17 UTC

Utili

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 mag 2026, 23:47 UTC

Utili

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 mag 2026, 23:45 UTC

Utili

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 mag 2026, 23:45 UTC

Utili

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 mag 2026, 23:40 UTC

Discorsi di Mercato

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 mag 2026, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 mag 2026, 22:43 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 mag 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 mag 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 mag 2026, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 mag 2026, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Shareholders to Own About 51% of Combined Company

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Board Unanimously Endorsed, Supported Deal

4 mag 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Deal Unanimously Recommended by Vault Board

4 mag 2026, 22:39 UTC

Acquisizioni, Fusioni, Takeovers

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 mag 2026, 22:38 UTC

Acquisizioni, Fusioni, Takeovers

Regis Resources to Acquire All Ordinary Shares in Vault

4 mag 2026, 22:38 UTC

Acquisizioni, Fusioni, Takeovers

Regis Resources, Vault Minerals Agree to Merger of Equals

4 mag 2026, 22:37 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 mag 2026, 22:26 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 mag 2026, 22:02 UTC

Utili

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 mag 2026, 22:00 UTC

Discorsi di Mercato

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 mag 2026, 21:52 UTC

Utili

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 mag 2026, 21:50 UTC

Utili

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 mag 2026, 21:50 UTC

Utili

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 mag 2026, 21:49 UTC

Utili

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 mag 2026, 21:44 UTC

Utili

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 mag 2026, 21:44 UTC

Utili

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 mag 2026, 21:43 UTC

Utili

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 mag 2026, 21:41 UTC

Utili

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 mag 2026, 21:40 UTC

Utili

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Confronto tra pari

Modifica del prezzo

Lantheus Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

8.23% in crescita

Previsioni per 12 mesi

Media 95 USD 8.23%

Alto 110 USD

Basso 85 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Lantheus Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

7

Acquista

1

Mantieni

0

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Lantheus Holdings Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

79.24 / 103.64Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

2 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Altri titoli del settore

JNJ

Johnson and Johnson

224.16

UNH

UnitedHealth Group Inc

370.76

TMO

Thermo Fisher Scientific Inc

462.35

ISRG

Intuitive Surgical Inc

452.39

ABT

Abbott Laboratories

87.56

Live chat